Clinical Trial Search

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: PFS — 29.8 Months

Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Efficacy of Belinostat in Terms of Complete or Partial Response; Disappearance of All Target Lesions or at Least a 30% Decrease in the Sum of the Longest Diameter of…

Primary: 6 Month Progression-free Survival (PFS) — 13 participants

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Overall Survival — 32 months

Primary: Tolerated Dose — 80 mg/m^2

Primary: Pathologic Complete Response Rates — 8 participants

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 3.6 percentage of evalubale patients

Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants

Primary: Progression-free Survival at 6 Months — 13.6 percentage of participants

Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Median Progression-free Survival — 3.2; 4.5 months

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Four Cycle Progression-free Survival Rate — 8 Participants

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Best Biochemical Response (Cancer Antigen [CA-125]) — 6; 25; 56; 3 percentage of participants

Primary: Progression-free Survival (PFS) > 6 Months — 8.0 percentage of participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Consolidation Progression-Free Survival — 13.3; 18.9 months

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Overall Survival — 0.35; 0.34; 0.39; 0.34 Proportion of participants

Primary: Tumor Response — 23.4 Percentage of participants